CTMS Portals: Letting Organizations Create More Collaborative Clinical Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
CTMS Portals: Letting Organizations Create More Collaborative Clinical Trials

Source: Applied Clinical Trials

This post first appeared on the BioOptronics, Inc. blog.

Collaboration is the way clinical research is moving. It can be seen through the collaborative technology for research sites, managing organizations and sponsors, but there are more people involved with each clinical trial. It is also critical that all research partners are included on this collaborative movement, and the only applications making this happen are CTMS applications.

Whether conducting research or managing research organizations, your organization is required to work with a variety of other organizations in order to successfully complete your trials. Working with a variety of organizations can become complex, especially if there is no way to centrally coordinate all of these interactions. With CTMS portals, organizations can easily stay on top of their partner interactions, leading to more accurate and timely trial completions.

CTMS portals are used to allow your partner organizations have access to certain information within your CTMS application so that they can utilize it to complete their parts of your trial. Along with this, your partners can provide the necessary materials that you need to move your trials forward. Portals allow both you and your partners the ability to communicate and collaborate at an unprecedented level.

Portals can be used by a variety of organizations. Sites that are not a part of your collaborative CTMS can use portals to communicate and share their data, documents, actions and milestones with your organization, and your organization can distribute central study protocols, as well as other essential information, to these sites.

Portals for sponsors can be created, allowing them to track the progress of your trials and run reports to ensure that everything related to the trial is operating as scheduled. For example, monitors and IRBs can also have portals connected to your CTMS. This allows your organization the ability to easily communicate with the IRB. Monitor portals allow your monitors to view and plan visits, complete online trip reports and share documents with ease. This allows your organization instant access to monitoring reports. In addition to this, your labs can have portals set up so that they can communicate and record any lab test results in real time.

With portals, your organization will experience a new level of collaboration with your research partners. What’s more, your processes will be more streamlined and efficient. Both you and your partners will now have access to all of their necessary data in real-time. This real-time sharing eliminates double data entry and eliminates the confusion about where your important data is stored. All of these benefits help eliminate errors and communication lapses between your organization and your research partners, saving your trials both time and money.

As the clinical research industry continues to evolve, all parties will look to becoming more collaborative in order to save time, save money and remain compliant. CTMS applications continue to make this collaboration possible, and the most advanced CTMS applications push this trend even further by including a multitude of research organizations on this collaboration through partner portals. As your organization continues to evolve, stay on the lookout for this trend and make sure to use the proper CTMS capable of meeting your collaborative needs.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here